- Home
- INMD vs ABUS Comparison
INMD vs ABUS Comparison
Compare INMD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMD | ABUS |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.2M | 848.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMD | ABUS |
|---|---|---|
| Price | $14.52 | $4.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $17.00 | $5.00 |
| AVG Volume (30 Days) | 581.0K | ★ 1.1M |
| Earning Date | 02-03-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $364,494,000.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | $6.56 | ★ N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $13.14 | $2.71 |
| 52 Week High | $19.78 | $5.10 |
Technical Indicators
Market Signals| Indicator | INMD | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 60.87 |
| Support Level | $14.24 | $4.43 |
| Resistance Level | $14.58 | $4.63 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 91.41 | 89.66 |
Price Performance
Historical ComparisonAbout INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.